论文部分内容阅读
目的：比较两种国产卡马西平（Ｃａｒｂａｍａｚｅｐｉｎｅ，ＣＢＺ）片（Ｂ，Ｃ）与北京ＣＩＢＡ－ＧＥＩＧＹ产得理多（Ｔｅｇｒｅｔｏｌ）片（Ａ）的人体相对生物利用度。方法：采用ＦＰＩＡ测定人血清ＣＢＺ浓度。１２名健康志愿者口服３００ｍｇＣＢＺ片，采用随机单盲同体交叉试验，进行Ｂ，Ｃ与Ａ人体相对生物利用度研究。结果：Ｂ，Ｃ对Ａ的相对生物利用度分别为（１００．７±２０．９）％，（１１０．２±２３．１）％；Ａ，Ｂ，Ｃ的Ｋａ分别为（０．１５±０．１１），（５．３±６．６）和（８．０±１５．３）ｈ－１，达峰时间（Ｔｍａｘ）分别为（１６．３±５．４），（３．４±３．８）和（２．３±１．９）ｈ；消除半衰期（Ｔ１／２）分别为（４２．０±９．９），（４２．１±１３．９）和（４１．６±１３．４）ｈ；血药浓度曲线下面积（ＡＵＣ０→∞）分别为（２６５．２±５９．４），（２６５．６±８２．３）和（２８６．１±７３．６）ｍｇ．ｈ．Ｌ－１。经统计学分析Ｂ，Ｃ与Ａ的Ｔｍａｘ，Ｋａ差异有极显著性（Ｐ＜０．０１），其余各参数差异均无显著性（Ｐ＞０．０５）。单次给药后，ＣＢＺ血药浓度－时间曲线出现双峰或多峰现象。结论：Ｂ，Ｃ生物等效，与Ａ生物不等效
OBJECTIVE: To compare the relative bioavailability of Carbamazepine (CBZ) tablets (B, C) with Beijing CIBA-GEIGY Tegretol tablets (A). Methods: The serum concentration of CBZ was measured by FPIA. 12 healthy volunteers oral administration of 300mgCBZ tablets, using a single-blind randomized cross-crossover study of B, C and A relative bioavailability of the human body. Results: The relative bioavailabilities of B and C to A were (100.7 ± 20.9)% and (110.2 ± 23.1)%, respectively. The Ka of A, B and C were (0.15 ± 0.11), (5.3 ± 6.6) and (8.0 ± 15.3) h-1 respectively. The peak time (Tmax) were (16.3 ± 5.4) and ± 3.8 and 2.3 ± 1.9 h respectively; the elimination half-lives (T1 / 2) were (42.0 ± 9.9), (42.1 ± 13.9) and ± 13.4) h. The area under the plasma concentration curve (AUC0 → ∞) were (265.2 ± 59.4), (265.6 ± 82.3) and (286.1 ± 73.6) mg . h L-1. Statistical analysis of B, C and A Tmax, Ka significant difference (P <0.01), the remaining parameters were no significant difference (P> 0.05). After a single dose, the CBZ plasma concentration-time curve appears bimodal or multimodal phenomenon. Conclusion: B and C are bioequivalent and not equivalent to A organisms